Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin

Although cholesteryl ester transfer protein (CETP) inhibition is regarded as a promising strategy to reduce atherosclerosis by increasing high-density lipoprotein cholesterol, the CETP inhibitor torcetrapib given in addition to atorvastatin had no effect on atherosclerosis and even increased cardiov...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2008-05, Vol.117 (19), p.2515-2522
Hauptverfasser:	DE HAAN, Willeke, DE VRIES-VAN DER WEIJ, Jitske, RENSEN, Patrick C. N, VAN DER HOORN, José W. A, GAUTIER, Thomas, VAN DER HOOGT, Caroline C, WESTERTERP, Marit, ROMIJN, Johannes A, JUKEMA, J. Wouter, HAVEKES, Louis M, PRINCEN, Hans M. G
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Atherosclerosis (general aspects, experimental research) Atherosclerosis - drug therapy Atherosclerosis - pathology Atorvastatin Calcium Biological and medical sciences Blood and lymphatic vessels Cardiology. Vascular system Cholesterol Ester Transfer Proteins - antagonists & inhibitors Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous Drug Synergism Heptanoic Acids - pharmacology Heptanoic Acids - therapeutic use Inflammation - chemically induced Medical sciences Mice Mice, Inbred Strains Pyrroles - pharmacology Pyrroles - therapeutic use Quinolines - pharmacology Quinolines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!